The rising cost of specialty drugs drove spending increases for people with multiple sclerosis

Author(s):: Johnson, Bill, author
Contributor(s):: Health Care Cost Institute, issuing body.
Publication:: Washington, DC : Health Care Cost Institute, April 2018
Language(s):: English
Format:: Text
Subject(s):: Drug Costs
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Multiple Sclerosis -- economics
Multiple Sclerosis -- drug therapy
Dihydroorotate Oxidase -- antagonists & inhibitors
Dimethyl Fumarate -- economics
Fingolimod Hydrochloride -- economics
Forecasting
Glatiramer Acetate -- economics
Interferon beta-1a -- economics
Interferon beta-1b -- economics
Humans
United States
Genre(s):: Technical Report
Copyright:: Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:: 1 online resource (1 PDF file (15 pages))
Illustrations:: Illustrations
NLM Unique ID:: 101744756 (See catalog record)
Permanent Link:: http://resource.nlm.nih.gov/101744756